propranolol has been researched along with Osteogenic Sarcoma in 4 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Osteosarcoma is still associated with limited response to standard-of-care therapy and alarmingly elevated mortality rates, especially in low- and middle-income countries." | 5.72 | Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy. ( Alonso, DF; Capobianco, CS; Ferrero, MR; Garona, J; Gottardo, MF; Sobol, NT; Solernó, LM; Vásquez, L, 2022) |
| " The ability of propranolol to modulate parathyroid hormone (PTH) and isoproterenol effects on adenylate cyclase activity and on alkaline phosphatase expression was studied in the osteoblast-like rat osteosarcoma cell line ROS 17/2." | 3.68 | Effects of beta-adrenergic blockade in an osteoblast-like cell line. ( Bastian, W; Einhorn, TA; Majeska, RJ; Minkowitz, B, 1992) |
| "Osteosarcoma is still associated with limited response to standard-of-care therapy and alarmingly elevated mortality rates, especially in low- and middle-income countries." | 1.72 | Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy. ( Alonso, DF; Capobianco, CS; Ferrero, MR; Garona, J; Gottardo, MF; Sobol, NT; Solernó, LM; Vásquez, L, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Solernó, LM | 1 |
| Sobol, NT | 1 |
| Gottardo, MF | 1 |
| Capobianco, CS | 1 |
| Ferrero, MR | 1 |
| Vásquez, L | 1 |
| Alonso, DF | 1 |
| Garona, J | 1 |
| Duckett, MM | 1 |
| Phung, SK | 1 |
| Nguyen, L | 1 |
| Khammanivong, A | 1 |
| Dickerson, E | 1 |
| Dusenbery, K | 1 |
| Lawrence, J | 1 |
| Majeska, RJ | 1 |
| Minkowitz, B | 1 |
| Bastian, W | 1 |
| Einhorn, TA | 1 |
| Pimm, MV | 1 |
4 other studies available for propranolol and Osteogenic Sarcoma
| Article | Year |
|---|---|
Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy.
Topics: Animals; Apoptosis; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Het | 2022 |
The adrenergic receptor antagonists propranolol and carvedilol decrease bone sarcoma cell viability and sustained carvedilol reduces clonogenic survival and increases radiosensitivity in canine osteosarcoma cells.
Topics: Adrenergic beta-Antagonists; Animals; Bone Neoplasms; Carvedilol; Cell Line, Tumor; Dog Diseases; Do | 2020 |
Effects of beta-adrenergic blockade in an osteoblast-like cell line.
Topics: Adenylyl Cyclases; Adrenergic beta-Antagonists; Alkaline Phosphatase; Animals; Bone Neoplasms; Dose- | 1992 |
An examination of the influence of vasoactive drugs on blood flow and localisation of a monoclonal antibody in human tumour xenografts.
Topics: Animals; Antibodies, Monoclonal; Humans; Mice; Mice, Nude; Neoplasms; Osteosarcoma; Pindolol; Propra | 1990 |